about
A randomized controlled trial comparing the effects of counseling and alarm device on HAART adherence and virologic outcomesCompartmentalization of HIV-1 within the female genital tract is due to monotypic and low-diversity variants not distinct viral populations.Incidence and correlates of HIV-1 RNA detection in the breast milk of women receiving HAART for the prevention of HIV-1 transmission.Oligonucleotide ligation assay detects HIV drug resistance associated with virologic failure among antiretroviral-naive adults in Kenya.HIV-1 shedding from the female genital tract is associated with increased Th1 cytokines/chemokines that maintain tissue homeostasis and proportions of CD8+FOXP3+ T cellsCorrelates of age at attainment of developmental milestones in HIV-infected infants receiving early antiretroviral therapy.High mortality in HIV-infected children diagnosed in hospital underscores need for faster diagnostic turnaround time in prevention of mother-to-child transmission of HIV (PMTCT) programsConsistency of Mycobacterium tuberculosis-specific interferon-gamma responses in HIV-1-infected women during pregnancy and postpartum.Nevirapine Resistance in Previously Nevirapine-Unexposed HIV-1-Infected Kenyan Infants Initiating Early Antiretroviral Therapy.Comparison of developmental milestone attainment in early treated HIV-infected infants versus HIV-unexposed infants: a prospective cohort study.The impact of HIV-1 infection and exposure on natural killer (NK) cell phenotype in Kenyan infants during the first year of life.A Pilot Study of Raltegravir Plus Combination Antiretroviral Therapy in Early Human Immunodeficiency Virus Infection: Challenges and Lessons Learned.Clinical and virologic manifestations of primary Epstein-Barr virus (EBV) infection in Kenyan infants born to HIV-infected women.Increasing HIV-1 pretreatment drug resistance among antiretroviral-naïve adults initiating treatment between 2006 and 2014 in Nairobi, Kenya.Lipid changes in Kenyan HIV-1-infected infants initiating highly active antiretroviral therapy by 1 year of ageSurvival benefit of early infant antiretroviral therapy is compromised when diagnosis is delayed.Pooled HIV-1 RNA viral load testing for detection of antiretroviral treatment failure in Kenyan children.HTLV-2 infection in injection drug users in King County, WashingtonAccelerated suppression of primary Epstein-Barr virus infection in HIV-infected infants initiating lopinavir/ritonavir-based versus nevirapine-based combination antiretroviral therapy.A national evaluation using standardised patient actors to assess STI services in public sector clinical sentinel surveillance facilities in South Africa.High Viremia and Wasting Before Antiretroviral Therapy Are Associated With Pneumonia in Early-Treated HIV-Infected Kenyan Infants.Treatment interruption after 2-year antiretroviral treatment initiated during acute/early HIV in infancy.Differences in virologic and immunologic response to antiretroviral therapy among HIV-1-infected infants and children.How often does treatment of primary HIV lead to post-treatment control?Factors predictive of significant hepatic fibrosis in adults with chronic hepatitis B and normal serum ALT.Decay of HIV DNA in the Reservoir and the Impact of Short Treatment Interruption in Kenyan Infants.No time to delay! Fiebig stages and referral in acute HIV infection: Seattle Primary Infection Program Experience.High Plasma Soluble CD163 During Infancy Is a Marker for Neurocognitive Outcomes in Early-Treated HIV-Infected ChildrenThe effect of a multidisciplinary program on HAART adherence
P50
Q28477310-4BB11124-0709-4B93-95C6-437A479D2A84Q33505667-C868ECEF-FB24-43B3-A96A-8299035F62CBQ34130621-EE7B4988-6F51-4B6A-B9A4-A3F21E97EC1CQ34339340-61150871-B784-4168-9B37-F71777FD8C0EQ34422185-734E28F2-067E-4FC2-92EA-8C9B75715328Q35106962-9A459F64-FF6F-4EA6-8887-CAEA8D3693E5Q35176855-D9C1566F-E069-4867-B723-FEBB5F924117Q35852451-B79CB1FA-C73C-4339-925E-E389929BB930Q35942341-4416B758-9DEE-4EB5-8D08-E7F34EC7FA83Q36251762-1A2309FD-5836-485E-AAF7-567BEA1A7053Q36496904-CDE41311-4C9B-46F2-8AFA-D6CE72FDB8EFQ36554974-188A8075-DA80-4040-8E75-E6BBFC66CF04Q36846242-3188010A-0003-4AE8-8329-6F22FEDD3B63Q36957786-A09A7CA2-148F-432D-8EF5-3365404BD5CEQ37080086-A0B1BC05-C02C-4534-A5CC-A6E1ED82323FQ37131384-3F2613A4-D1FA-418A-B6C8-ED1148D04227Q37156124-648F1AAF-7556-4ACB-B019-AC24CC52F479Q37196486-1AF1E2B0-0DB6-4702-9514-81B15DCF3418Q37696585-E636AE6D-E554-44E8-8FDF-140B1E054ED7Q38373850-4D9FA9A8-A69E-47B9-8841-FCF9FAE93F4DQ39535039-2A830867-BF99-426D-A249-68DF7BD3ABA8Q39768190-57D5E264-4BE6-4A49-8631-C60A22B39349Q40548877-7E3247E9-17AE-4D84-BD23-AE6D1EE1D190Q41023177-654CB3E1-8398-466C-A8D8-420977EAB3EDQ46610596-0BED4E61-FD9A-4002-BD06-C296EE543CA5Q49888173-52269C90-53A9-4E0D-A064-571154EAD7C8Q53871083-2B45C499-9FDC-4F7D-8280-CE848305F241Q64129975-1EE90434-5815-4CB2-884C-4C086BDCE3C7Q79898423-D68E1803-91F3-4C45-9BBD-41BB5DA55E9C
P50
name
Kenneth Tapia
@en
type
label
Kenneth Tapia
@en
prefLabel
Kenneth Tapia
@en